HomeCompareFRC vs ABBV

FRC vs ABBV: Dividend Comparison 2026

FRC yields 23.08% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRC wins by $2561601.87M in total portfolio value
10 years
FRC
FRC
● Live price
23.08%
Share price
$3.51
Annual div
$0.81
5Y div CAGR
83%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2561601.97M
Annual income
$2,510,790,767,801.48
Full FRC calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — FRC vs ABBV

📍 FRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRC
Annual income on $10K today (after 15% tax)
$1,961.54/yr
After 10yr DRIP, annual income (after tax)
$2,134,172,152,631.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, FRC beats the other by $2,134,172,130,764.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRC + ABBV for your $10,000?

FRC: 50%ABBV: 50%
100% ABBV50/50100% FRC
Portfolio after 10yr
$1280801.04M
Annual income
$1,255,395,396,763.60/yr
Blended yield
98.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FRC
No analyst data
Price Target
$167.33
+4667.2% upside vs current
Range: $8.00 — $250.00
Altman Z
-0.4
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRC buys
0
ABBV buys
0
No recent congressional trades found for FRC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRCABBV
Forward yield23.08%3.12%
Annual dividend / share$0.81$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR83%40.6%
Portfolio after 10y$2561601.97M$104.7K
Annual income after 10y$2,510,790,767,801.48$25,725.73
Total dividends collected$2558167.96M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst price target$167.33$256.15

Year-by-year: FRC vs ABBV ($10,000, DRIP)

YearFRC PortfolioFRC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,923$4,223.08$11,559$438.51+$3.4KFRC
2$26,746$10,778.41$13,494$640.86+$13.3KFRC
3$61,657$33,038.79$15,951$945.97+$45.7KFRC
4$196,234$130,260.92$19,152$1,413.89+$177.1KFRC
5$919,013$709,043.01$23,443$2,146.38+$895.6KFRC
6$6,662,548$5,679,203.20$29,391$3,321.96+$6.63MFRC
7$77,545,223$70,416,297.60$37,948$5,265.87+$77.51MFRC
8$1,484,673,890$1,401,700,500.55$50,795$8,596.74+$1484.62MFRC
9$47,487,108,109$45,898,507,046.81$71,034$14,549.41+$47487.04MFRC
10$2,561,601,973,478$2,510,790,767,801.48$104,715$25,725.73+$2561601.87MFRC

FRC vs ABBV: Complete Analysis 2026

FRCStock

First Republic Bank, together with its subsidiaries, provides private banking, private business banking, and private wealth management services to clients in metropolitan areas in the United States. It operates in two segments, Commercial Banking and Wealth Management. The company accepts deposit products, such as noninterest-bearing checking, interest-bearing checking, money market checking accounts, money market savings accounts, and passbook accounts, as well as certificates of deposit. It also offers a range of lending products that comprise residential mortgage loans, home equity lines of credit, multifamily loans, commercial real estate and construction loans, personal and business loans, single family construction loans, and other loans and lines of credit to businesses and individuals. The company's loans are secured by single family residences, multifamily buildings, and commercial real estate properties. In addition, it provides wealth management services, which include various investment strategies and products, online investment management, trust and custody, full service and online brokerage, financial and estate planning, and access to alternative investments, as well as investing, insurance, and foreign exchange services. Further, the company offers online and mobile banking services; refinancing services; and ATM and debit cards. As of December 31, 2021, it offered its services through 82 licensed deposit taking offices primarily in the San Francisco, Palo Alto, Los Angeles, Santa Barbara, Newport Beach and San Diego, California; Portland, Oregon; Boston, Massachusetts; Palm Beach, Florida; Greenwich, Connecticut; New York, New York; and Jackson, Wyoming. It also has 12 additional offices that offer lending, wealth management, or trust services. First Republic Bank was founded in 1985 and is headquartered in San Francisco, California.

Full FRC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FRC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRC vs SCHDFRC vs JEPIFRC vs OFRC vs KOFRC vs MAINFRC vs JNJFRC vs MRKFRC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.